Inflammatory diseases treated by interleukin 1 (IL-1) blockade
| Disease | Pathology | Response to IL-1 blockade? |
|---|---|---|
| Cryopyrin-associated periodic syndrome | ||
| Muckle–Wells syndrome | NLRP3 mutations | Canakinumab4 |
| Anakinra5 | ||
| Rilonacept6 | ||
| Familial Mediterranean fever | MEFV mutations | Anakinra7 |
| Canakinumab7 | ||
| Tumour necrosis factor receptor-associated periodic syndrome (TRAPS) | TNFR1 | Anakinra8 |
| Deficiency of interleukin-1 receptor antagonist | IL-1Ra deficiency | Anakinra9 |
| Autoimmune diseases | ||
| Rheumatoid arthritis | Unclear | Anakinra10 |
| Canakinumab11 | ||
| Still's disease | Idiopathic | Anakinra12 |
| Canakinumab13 | ||
| Diseases with inflammatory aspects | ||
| Type 2 diabetes | Anakinra14 | |
| Atherosclerosis | Cholesterol as NLRP3 activator | Canakinumab Anti-inflammatory Thrombosis Outcomes Study, MRC-ILA-HEART (results pending) |
| Gout | Uric acid as NLRP3 activator | Anakinra15 |
| Canakinumab16 | ||
| Rilonacept17 | ||
| Schnitzler syndrome | Unclear | Anakinra18 |